British Cannabis , a private cannabidiol manufacturer, is currently the best choice in the UK's Cannabidiol sweepstakes. A total of 310 products that are associated with BRITISH CANNABIS were recently advanced to regulators. The Food Standards Agency (FSA) released a list earlier this month.
The Berkshire-based company was approved for 75 products it submitted alone and 235 that it submitted in collaboration with other companies. As reported by the List, which was released on March 31, 3,536 products were approved by FSA preliminarily as "novel" or new foods.
RX Pharmatech Ltd. from Bradford, West Yorkshire has 273 products approved by it. This is the second-highest number. RX Pharmatech submitted 11 products by itself and 157 with other producers.
According to the Association for the Cannabinoid Industry. (ACI), the UK market for CBD products was worth PS690million. ACI reported that CBD sales have more than doubled in UK over the past year, making it the non-EU's second largest consumer market, after the USA.
In total, 374 companies had products approved by the FSA. Some companies applied separately; others were only participants in joint applications filed with other producers. Other companies also filed independent applications. Some filed separately while others filed jointly There were 70 CBD applications submitted to the FSA.
Although products that were included on the list may be allowed to continue selling, products that failed FSA scrutiny will not be permitted to remain on the market. FSA stressed that approvals are preliminary, some products may be removed during the later stages of their review.
The majority of these products were moved to pre-validation ("awaiting evidence") status, which is the second stage in the FSA's novel foods approval process. FSA has now approved 57 products from five companies.
You are looking for clarity
FSA's novel approval process for food is first and foremost designed to clarify the grey market in CBD that has seen thousands more cannabidol products pop up in shops over the years. FSA guidelines stipulate those products in distribution must have been available before February 13, 2020. Products introduced after that date would not be eligible for consideration.
According to the Association's website, British Cannabis products were likely obtained through a consortium that was organized by the ACI. ACI declined to provide information on the number of products that were sent through its consortium. It also refused to disclose the names or numbers of the applicants (FPs) submitted by the companies. ACI's members list at least 628 products, which includes British Cannabis, among those that advanced.
Applications of EIHA
RX Pharmatech was submitted products by a separate consortium to the European Industrial Hemp Association.
EIHA Projects GmbH received products submitted by 193 companies This account for approximately 56% of all advanced products. The applications covered both full-spectrum extracts (835) and isolates (1,157).
A quick look at the top companies
Here's a list of the top five companies that were associated with the complete list of 3,536 products, these are based on how many products they had been approved by FSA according to company websites.
British cannabis oil
British Cannabis was established by an independent company, which is vertically integrated and produces marijuana, CBD and other cannabis products.British Cannabis supplies white-label products to other brands and makes its own brand products. BRITISH CANNABIS operates its own laboratory, manufacturing facility and warehouse, the company also has dispatch operations and a farm for cannabis research in Portugal. The company claims that it has shipped more than 50k bottles of CBD oils between its two largest white label clients. BRITISH CANNABIS announced its intention to invest in a new facility. It will include an ISO-accredited cannabis analytics testing lab and a cosmetics line. This could increase its potential capacity by up to three times. One of the 35 UK government "chemist rings trial" testing labs is used to measure Cannabidol and cannabinoid levels in commercial products.
Associated principals : Thomas Whettem CEO & Founder, David Ralston, Managing director
RX Pharmatech Ltd
RX Pharmatech Ltd. doesn't appear to have a website, and very little public information about it is available Other sources confirm that the company was formed in May 2016. RX Pharmatech is a supplier for bulk isolates, and distillates manufactured by GVB Biopharma in Las Vegas, Nevada, USA. RX Pharmatech is a party to the FSA's second-highest product list. GVB also claimed in a press statement April 7, 2022, that it is the largest supplier to white label formulas for oral tinctures and vape liquids. GVB stated it sources raw material from a U.S. farmers' cooperative. GVB's website states that the company has a UK branch in Doncaster (Yorkshire, England). GVB has one investor: Decathlon Kapital Partners, a growth equity business based out of Park City, Utah. GVB claims to also have operations in Europe (location unknown) and Bogota in Colombia. GVB Biopharma has joined Medicaleaf Ltd. in Cheltenham and Gloucestershire, as well as Isomist Ltd. in London, to submit three products for FSA approval. GVB Biopharma has been reported to have in a strategic partnership with Sonder Fulfillment. Sonder Fulfillment a division Golden Triangle Ventures, a Las Vegas-based pennystock company.
Principals associated with RX Pharmatech Ltd. Dominic James Bartle is the director and Damien Jonathan Bove is the director. GVB Biopharma Phillip Swindells is the CEO and co-founder. Jack Feldman is president & Co-founder. Hugh Kinsman is CFO.
Mile High Labs
Mile High Labs, a supplier of CBD and CBN in Colorado, is located in Broomfield. Mile High reported in 2019 that it had raised $100 million total in funding via two rounds. Mile High owns an extraction facility that uses raw materials obtained from a network in the USA of CBD hemp growers. According to the company website, it also has a Belfast office.
Associated principals Jonathan Hilley CEO, Ryan Keeler COO, Jodi Gatica VP Quality, Danny Moses, Investor.
Taylor Mammon Ltd
Taylor Mammon Ltd. is a white-label distributor and manufacturer of CBD. It is based in Welwyn Garden City (Hertfordshire). The parent company is based in Kentucky and operates under the name of OGGUSA Inc. GenCanna crashed in 2020 when it filed bankruptcy amid a series of lawsuits from creditors who claimed that the company owed them between $100 and 500 million. In May 2020, GenCanna's majority of assets were sold to MGG Investment Group in New York. In May 2020 the bankruptcy court approved GenCanna’s sale to MGG Investment Group, New York. GenCanna purchased Taylor Mammon's UK-based CBD Capital in the last year.
Associated principals : Taylor Mammon - Alex Taylor, cofounder; James Taylor chief commercial officer; Nathan Wogman cofounder and managing director. GenCanna/OGGUSA Inc. - Andrew Barnett, CEO; Hassan Akhtar, managing director, Europe.
Sativa Wellness Group
The company, now known as Goodbody Health Inc., has submitted its novel food applications under Sativa Wellness. It is an OTC traded manufacturer of approximately 20 cannabidol products. They sell oils, capsules and gummies online, and have laboratories to test CBD products in the UK. There are also laboratories in the UK and Poland for testing CBD products.Goodbody/Sativa Wellness headquarters is located in Vancouver (British Columbia), with an office in Beckington, Somerset. In 2020, the company suffered a loss of almost $6.5 million (PS5 millions) according to public financial reports. Goodbody shares trade at $0.05 (5c) currently. Goodbody's UK subsidiary, PhytoVista Laboratories (April 2022) was granted a controlled-drug license.
Associated principals (Goodbody Health Inc.): Geremy Tom, Founder & Executive Chair; Marc Howells CEO; Anne Tew CFO and Corporate Secretary.